FeNO’s Clinical Usefulness


FENO MeasurementAsthma is a giant among health care concerns. It affects an estimated 20 million Americans, 300 million people worldwide, and 10 percent of all children.1 The most common chronic lung disease of childhood, asthma’s prevalence and morbidity are on the rise; the death rate for asthmatic children under 19 years old has increased by nearly 80 percent since 1980.2

In this live webinar presentation, discover the usefulness of the FeNO biomarker in asthma management. There will be 15 minutes for questions at the conclusion of the presentation.

Speaker: Gabe Ortiz, MPAS, PA-C, DFAAPA

Date/Time: August 8 • 1 to 2 p.m.

Where: Your computer screen

Free!

##MM_VIDEO_ARTICLE_080912_RS_1##

This webinar is supported by an educational grant from
About the Speaker: Gabriel Ortiz, MPAS, PA-C, DFAAPA, is the liaison between the American Academy of Physicians Assistants (AAPA) and the American Academy of Allergy, Asthma and Immunology (AAAAI). He is the former AAPA Liaison to the National Institutes of Health-National Asthma Education and Prevention Program – Coordinating Committee.

Looking for more online educational opportunities? See what’s next on our webinar schedule or check out our archived events.

About The Author